The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Brain voltage-gated sodium channel NaV1.1 (SCN1A) loss-of-function variants cause the severe epilepsy Dravet syndrome, as well as milder phenotypes associated with genetic epilepsy with febrile seizures plus. Gain of function SCN1A variants are associated with familial hemiplegic migraine type 3. Novel SCN1A-related phenotypes have been described including early infantile developmental and epileptic encephalopathy with movement disorder, and more recently neonatal presentations with arthrogryposis. Here we describe the clinical, genetic and functional evaluation of affected individuals. Thirty-five patients were ascertained via an international collaborative network using a structured clinical questionnaire and from the literature. We performed whole-cell voltage-clamp electrophysiological recordings comparing sodium channels containing wild-type versus variant NaV1.1 subunits. Findings were related to Dravet syndrome and familial hemiplegic migraine type 3 variants. We identified three distinct clinical presentations differing by age at onset and presence of arthrogryposis and/or movement disorder. The most severely affected infants (n = 13) presented with congenital arthrogryposis, neonatal onset epilepsy in the first 3 days of life, tonic seizures and apnoeas, accompanied by a significant movement disorder and profound intellectual disability. Twenty-one patients presented later, between 2 weeks and 3 months of age, with a severe early infantile developmental and epileptic encephalopathy and a movement disorder. One patient presented after 3 months with developmental and epileptic encephalopathy only. Associated SCN1A variants cluster in regions of channel inactivation associated with gain of function, different to Dravet syndrome variants (odds ratio = 17.8; confidence interval = 5.4–69.3; P = 1.3 × 10−7). Functional studies of both epilepsy and familial hemiplegic migraine type 3 variants reveal alterations of gating properties in keeping with neuronal hyperexcitability. While epilepsy variants result in a moderate increase in action current amplitude consistent with mild gain of function, familial hemiplegic migraine type 3 variants induce a larger effect on gating properties, in particular the increase of persistent current, resulting in a large increase of action current amplitude, consistent with stronger gain of function. Clinically, 13 out of 16 (81%) gain of function variants were associated with a reduction in seizures in response to sodium channel blocker treatment (carbamazepine, oxcarbazepine, phenytoin, lamotrigine or lacosamide) without evidence of symptom exacerbation. Our study expands the spectrum of gain of function SCN1A-related epilepsy phenotypes, defines key clinical features, provides novel insights into the underlying disease mechanisms between SCN1A-related epilepsy and familial hemiplegic migraine type 3, and identifies sodium channel blockers as potentially efficacious therapies. Gain of function disease should be considered in early onset epilepsies with a pathogenic SCN1A variant and non-Dravet syndrome phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recently, a new type of Early Infantile DEE (EIDEE) was identified that is caused by gain of function (GOF) SCN1A pathogenic variants with onset by three months 32,33 .”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“SCN1A again provides a good example with Dravet syndrome arising due to LOF pathogenic variants 169 , and GOF pathogenic variants causing a profound Early Infantile DEE with an expanded phenotypic spectrum 32,33 .”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“SCBs, particularly carbamazepine and phenytoin, are efficacious in GOF-DEEs due to pathogenic variants in sodium channel (SCN1A 33 , SCN2A 184 and SCN8A 185 ) and potassium channel (KCNQ2 43 ) genes.”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 58 · Cited by 167
Metadata
- Authors
- Brunklaus, A., Brünger, T., Feng, T., Fons, C., Lehikoinen, A., Panagiotakaki, E., Vintan, M.-A., Symonds, J., Andrew, J., Arzimanoglou, A., Delima, S., Gallois, J., Hanrahan, D., Lesca, G., MacLeod, S., Marjanovic, D., McTague, A., Nuñez-Enamorado, N., Perez-Palma, E., Scott Perry, M., Pysden, K., Russ-Hall, S. J., Scheffer, I. E., Sully, K., Syrbe, S., Vaher, U., Velayutham, M., Vogt, J., Weiss, S., Wirrell, E., Zuberi, S. M., Lal, D., Møller, R. S., Mantegazza, M., & Cestèle, S.
- Affiliations
- Royal Hospital for Children (GB)
- University of Cologne (DE)
- Instituto de Salud Carlos III (ES)
- Kuopio University Hospital (FI)
- Centre National de la Recherche Scientifique (FR)
- ‘Iuliu Hatieganu’ University of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology and Pediatric Neurology , Victor Babes, 43, 400012 Cluj-Napoca , Romania
- Indiana University Health (US)
- Louisiana State University (US)
- Royal Belfast Hospital for Sick Children (GB)
- Department of Medical Genetics, Lyon University Hospital, Member of the ERN EpiCARE , Université Claude Bernard Lyon 1, Lyon , France
- The Danish Epilepsy Centre, Member of the ERN EpiCARE , Dianalund , Denmark
- Great Ormond Street Hospital (GB)
- Pediatric Neurology Department, 12 Octubre Universitary Hospital , Madrid , Spain
- Universidad del Desarrollo, Centro de Genética y Genómica, Facultad de Medicina Clínica Alemana , Santiago , Chile
- Jane and John Justin Neurosciences Center, Cook Children’s Medical Center , Ft Worth, TX , USA
- Leeds General Infirmary (GB)
- The University of Melbourne (AU)
- Royal Children's Hospital (AU)
- Baylor College of Medicine (US)
- University Hospital Heidelberg (DE)
- Tartu University Hospital (EE)
- Birmingham Children's Hospital (GB)
- Birmingham Women's Hospital (GB)
- University of Toronto (CA)
- Mayo Clinic (US)
- Broad Institute (US)
- University of Southern Denmark (DK)
- Corresponding author
- Brunklaus, Andreas
- Møller, Rikke S
- Mantegazza, Massimo
- Cestèle, Sandrine
- ORCID
- Brunklaus, Andreas
- Fons, Carmen
- Lehikoinen, Anni
- Panagiotakaki, Eleni
- Symonds, Joseph
- Arzimanoglou, Alexis
- Delima, Sarah
- McTague, Amy
- Pysden, Karen
- Russ-Hall, Sophie J
- Scheffer, Ingrid E
- Sully, Krystal
- Syrbe, Steffen
- Vaher, Ulvi
- Vogt, Julie
- Weiss, Shelly
- Wirrell, Elaine
- Zuberi, Sameer M
- Lal, Dennis
- Møller, Rikke S
- Mantegazza, Massimo
- Cestèle, Sandrine
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-06-13
- Volume
- 145
- Issue
- 11
- Pages
- 3816-3831
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC9679167
- OpenAlex
- W4282598224
- Cited by
- 167
- References
- 58
- Citations by year
- 2026: 36 · 2025: 54 · 2024: 40 · 2023: 29 · 2022: 8
- FWCI
- 21.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by-nc)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- HAL (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc)
- Funders
- Dravet Syndrome Foundation (272016)
- BMBF (01GM1907)
- NIH
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- SCN1A, Nav1.1, gain-of-function mutations, Dravet syndrome, genetic epilepsy with febrile seizures plus, developmental and epileptic encephalopathy, arthrogryposis, movement disorders, sodium channel gating, persistent sodium current, neuronal hyperexcitability, sodium channel blockers, carbamazepine
- MeSH terms
- Epileptic Syndromes, Gain of Function Mutation, Arthrogryposis, Epilepsy, Epilepsies, Myoclonic, Humans, Infant, Infant, Newborn, Movement Disorders, Phenotype, Spasms, Infantile, Migraine with Aura, NAV1.1 Voltage-Gated Sodium Channel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications. https://app.cochat.ai/papers/10.1093/brain/awac210
- The paper
- Brunklaus, A., Brünger, T., Feng, T., Fons, C., Lehikoinen, A., Panagiotakaki, E., Vintan, M.-A., Symonds, J., Andrew, J., Arzimanoglou, A., Delima, S., Gallois, J., Hanrahan, D., Lesca, G., MacLeod, S., Marjanovic, D., McTague, A., Nuñez-Enamorado, N., Perez-Palma, E., . . . Cestèle, S. (2022). The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications. Brain. https://doi.org/10.1093/brain/awac210
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.